Related Experiment Videos
[The study on radiotherapy for hepatocellular carcinoma]
Nihon Igaku Hoshasen Gakkai Zasshi. Nippon Acta Radiologica
|September 25, 1989
Summary
Radiotherapy effectively treats hepatocellular carcinoma (HCC), with minimal hepatic side effects. A Time-Dose-Fractionation factor (TDF) of 80 or higher is recommended for optimal tumor regression and improved survival, especially for tumor emboli.
Area of Science:
- Hepatobiliary Medicine
- Radiation Oncology
- Clinical Oncology
Context:
- Hepatocellular carcinoma (HCC) presents significant treatment challenges.
- Radiotherapy is an established modality for various cancers.
- The specific efficacy and safety of involved-field radiotherapy for HCC require detailed clinical assessment.
Purpose:
- To evaluate the clinical effects and adverse reactions of involved-field radiotherapy in HCC patients.
- To determine optimal radiation parameters (dose, field size) for HCC treatment.
- To assess the impact of radiotherapy on patient prognosis and survival.
Summary:
- Involved-field radiotherapy was administered to 27 HCC cases, with minimal impact on hepatic functions.
- Tumor regression was observed in 82% of primary tumors and 92% of tumor emboli.
- Histological improvements (at least stage IIA) were noted in 88% of primary tumors and 80% of tumor emboli, particularly with a Time-Dose-Fractionation factor (TDF) of 80 or higher.
- A treatment field of 8x8 cm or smaller was found to be safe at TDF 80.
- Radiotherapy significantly prolonged survival in non-resected HCC with tumor emboli.
Impact:
- Establishes TDF 80 as a benchmark for effective HCC radiotherapy.
- Highlights the safety and efficacy of focused radiotherapy fields (≤8x8 cm).
- Demonstrates radiotherapy's value in improving survival for unresectable HCC, especially with tumor emboli.